Project Grant R21CA303427
Award Date 6/24/26
Completion Date 5/31/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $687,291 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award funds fundamental research investigating how cancer driver mutations—specifically MLL3 (also known as KMT2C) loss combined with PI3KCA activation and P53 inactivation—promote immune suppression in breast cancer through regulatory T (Treg) cell...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $219,372 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 11, 2026, with an ultimate completion date of April 30, 2031. This five-year career development and research initiative supports a surgeon-scientist at Montefiore Medical Center in the Bronx to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $645,185 Project Grant on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an innovative immunotherapy approach for glioblastoma (GBM), a highly aggressive brain tumor with poor patient survival outcomes. The research, titled "Expand and Pull: Long-Acting IL-7 and Oncolytic Virus to Treat Glioblastoma," focuses on combining long-acting...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Wistar Institute of Anatomy and Biology a Project Grant totaling $651,940 under the Cancer Treatment Research program (CFDA 93.395) to conduct fundamental research elucidating targetable mechanisms that sustain immunosuppressive neutrophils in the glioblastoma (GBM) tumor microenvironment. The award, obligated on May 19, 2026, with an ultimate completion date of April 30, 2031, supports research designed to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell immunogenicity in glioblastoma. The project, which extends through May 31, 2029, will expose glioblastoma neurosphere models to 3,792 small molecules targeting diverse cellular activities and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $683,256 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 22, 2026, with a completion date of April 30, 2031. This award funds a human-mouse platform initiative designed to advance patient stratification, target discovery, and validation in glioblastoma (GBM) treatment. The project addresses the critical challenge of tumor heterogeneity by integrating...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, through April 30, 2031. The award supports research and development of MTAP (methylthioadenosine phosphorylase) transition state analog inhibitors as a novel synthetic-lethal therapeutic approach for cancer treatment. The research focuses on developing highly specific,...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. This award supports research investigating dual-targeting therapeutic approaches for acute myeloid leukemia (AML), combining BCL-2 inhibition with CD123-directed natural killer (NK) cell engager technology. The research will evaluate the combinatorial...
- Federal Project Grant Award Summary The National Cancer Institute, under its Cancer Treatment Research program (CFDA 93.395), awarded $414,402 to the University of California, San Francisco on May 1, 2026, for a two-year research project completing April 30, 2028. This project develops an integrated computational framework to improve glioblastoma radiation therapy targeting by combining diffusion tensor imaging (DTI) analysis with molecular biomarkers. Specifically, the research team will create...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG). The award, effective April 1, 2026 through March 31, 2028, supports the development and characterization of novel humanized TROP2 mouse...